Cargando…

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide. Promising new therapies have recently emerged from the development of molecular targeted drugs; particularly promising are those blocking the signal transduction machinery of cancer cells. One of the most widely studied cell signal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopes, Gabriel Lima, Vattimo, Edoardo Filippo de Queiroz, de Castro, Gilberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635957/ https://www.ncbi.nlm.nih.gov/pubmed/26398757 http://dx.doi.org/10.1590/S1806-37132015000004531

Ejemplares similares

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
por: Haaland, Benjamin, et al.
Publicado: (2014)

EGFR mutations in sinonasal squamous tumors: oncogenic and therapeutic implications
por: Udager, Aaron M., et al.
Publicado: (2015)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
por: Fang, Shu, et al.
Publicado: (2014)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

Metastatic Lung Adenocarcinoma Harboring an EGFR-Activating Mutation in a Heart Transplant Recipient
por: Zambrano Mendoza, Elizabeth, et al.
Publicado: (2017)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
por: Lin, Chun-Yu, et al.
Publicado: (2017)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
por: Montella, Tatiane, et al.
Publicado: (2023)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
por: Fu, Kai, et al.
Publicado: (2022)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer
por: Kim, Jung Soo, et al.
Publicado: (2017)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Conforti, Fabio, et al.
Publicado: (2020)

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
por: Matsumoto, Yoshiya, et al.
Publicado: (2022)

Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation
por: Jang, Seung Hun
Publicado: (2014)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
por: Hakozaki, Taiki, et al.
Publicado: (2020)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Black esophagus: exploring the dark
por: Forster, Robert, et al.
Publicado: (2013)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
por: Koulouris, Andreas, et al.
Publicado: (2022)

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
por: Pan, Binyang, et al.
Publicado: (2023)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
por: Pathak, Ranjan, et al.
Publicado: (2021)

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
por: Kim, Insu, et al.
Publicado: (2019)

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
por: Isla, D., et al.
Publicado: (2020)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations
por: Leal, Letícia Ferro, et al.
Publicado: (2019)

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer
por: Tong, Bing, et al.
Publicado: (2018)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
por: Ali, Azhar, et al.
Publicado: (2018)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
por: Rosell, Rafael, et al.
Publicado: (2021)

TERT Mutations in Non–Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Implications
por: Yang, Liu, et al.
Publicado: (2023)

Detecting EGFR Mutations in Patients with Non-small Cell Lung Cancer
por: Hammoudeh, ZA, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sqddtat859c6v141pnc0fhvq3b